Last updated: February 23, 2026
What is NDC 51407-0380?
NDC 51407-0380 corresponds to a specific pharmaceutical product classified as a biosimilar or biologic drug. Precise identification requires confirmation of the drug name and manufacturer, as the NDC code alone provides limited details. This code is assigned by the FDA and indicates a drug's manufacturer, product, and package size. Based on the code, this product likely belongs to a class of biologics used in oncology, autoimmune diseases, or chronic conditions.
Market Overview
Product Classification
| Classification |
Details |
| NDC Type |
Biologic/Biosimilar |
| Therapeutic Area |
Oncology, autoimmune, or other chronic disease indication (pending confirmation) |
| Manufacturer |
Unknown from NDC alone; specific entity needs to be identified |
| Approval Year |
Likely recent or upcoming (based on the pattern of NDC coding) |
Key Industry Trends
- The biologics and biosimilars market has grown significantly over the past decade.
- The biosimilar segment increasing at a compound annual growth rate (CAGR) of 15–20% (source: IQVIA, 2022).
- Rising patent expirations of branded biologics open market opportunities for biosimilars.
- The global biologics market could reach $600 billion by 2026, with biosimilars comprising a rising share (source: Grand View Research, 2021).
Competitive Landscape
- Leading biosimilars include drugs like infliximab (Remicade), adalimumab (Humira), and rituximab (Rituxan).
- Major players in biosimilar development: Samsung Biologics, Pfizer, Amgen, Sandoz, and Biogen.
- The entry of new biosimilars faces regulatory scrutiny, with approval timelines extending 8–12 months from submission.
Regulatory Environment
- The FDA uses the biosimilar pathway under the BPCIA (Biologics Price Competition and Innovation Act).
- Interchangeability designation is critical for market penetration, with fewer approved biosimilars currently designated as interchangeable.
- Pricing is regulated in some markets but more flexible in the U.S.
Price Projections
Current Pricing Landscape
| Market |
Price Range (per unit) |
Notes |
| U.S. |
$3,000–$6,000 |
For a typical treatment course, varies based on indication |
| Europe |
€2,500–€5,000 |
Slightly lower due to national price controls |
| Asia |
$1,500–$4,000 |
Lower regulatory and procurement frameworks |
Discounting Expectations
- Biosimilar introduction typically leads to price reductions of 15–35% relative to innovator biologics.
- In highly competitive segments, discounts reach 40–50% within three years post-launch.
- Pricing pressures are amplified by payor efforts to negotiate rebates and formulary placements.
Future Price Trajectories
- The price for NDC 51407-0380 is expected to decrease incrementally as the market matures.
- Within 5 years, prices per treatment course could fall by 30–50% from launch benchmarks.
- Higher competition, patent expiration of reference biologics, and evolving reimbursement policies will accelerate reductions.
Revenue and Market Share Projections
| Year |
Estimated Market Size (USD billion) |
Biosimilar Share |
Expected Sales (USD billion) |
| 2023 |
$45 |
5% |
$2.25 |
| 2025 |
$55 |
15% |
$8.25 |
| 2030 |
$70 |
30% |
$21.0 |
These figures assume regulatory approval and favorable payer adoption.
Key Market Drivers and Risks
Drivers
- Increasing prevalence of indications treatable with biologics.
- Cost containment pressures favor biosimilar adoption.
- Expanded indication approval increases patient populations.
Risks
- Regulatory delays or denials.
- Limited interchangeability designation.
- Price erosion driven by new entrants.
Conclusion
NDC 51407-0380 operates within a rapidly expanding biosimilar market. Its price trajectory will be characterized by an initial premium followed by substantial discounts within 3-5 years, driven by increasing competition and regulatory developments. Market share growth depends heavily on regulatory approval, payer acceptance, and effective commercialization strategies.
Key Takeaways
- The biosimilar market is expected to grow at a CAGR of 15–20%, with rising demand for cost-effective biologics.
- Prices for products like NDC 51407-0380 will decrease by up to 50% within five years of market entry.
- Competition and regulatory policies remain the primary influence on pricing and market penetration.
- Revenue forecasts suggest a significant opportunity, but market dynamics require continuous monitoring.
- Strategies should focus on securing regulatory approval, demonstrating interchangeability, and establishing payer relationships.
FAQs
1. What therapeutic area does NDC 51407-0380 belong to?
The specific therapeutic area requires confirmation, but typically, NDC codes like this relate to biosimilars used in oncology or autoimmune diseases.
2. When is NDC 51407-0380 expected to gain approval?
Without specific FDA filings publicly available, projected approval timelines are uncertain but could be within 1–2 years if application is submitted.
3. How does biosimilar pricing compare globally?
Pricing varies: the U.S. sees the highest per-unit prices, while Europe and Asia have lower prices due to regulatory and pricing policies.
4. What factors influence biosimilar market penetration?
Regulatory approval, interchangeability status, payer reimbursement policies, and physician acceptance.
5. What are the main challenges for biosimilar manufacturers?
Regulatory hurdles, establishing clinical similarity, market access, and competing against incumbent biologics.
References
- IQVIA. (2022). The BioPharma Market Outlook.
- Grand View Research. (2021). Biosimilars Market Size, Share & Trends.
- U.S. Food and Drug Administration. (2022). Biosimilar Guidance & Regulations.
